Anti-androgens bicalutamide and enzalutamide, target the androgen receptor (AR) in various TNBC cell lines which further inhibited proliferation, invasion and migration of cancer cells suggested them as a surrogate biomarker for response to other therapies [115].Voltage-gated sodium channel (VGSC) isneonatal splice variant of the VGS subtype Nav1. The gene discussed is AR; the disease is cancer.